NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD
6.34
-0.33 (-5.02%)
The current stock price of UNCY is 6.34 USD. In the past month the price increased by 11.23%. In the past year, price decreased by -0.22%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.04 | 327.31B | ||
AMGN | AMGEN INC | 13.94 | 155.58B | ||
GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.33 | 26.73B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
NTRA | NATERA INC | N/A | 23.47B | ||
INSM | INSMED INC | N/A | 18.70B | ||
BIIB | BIOGEN INC | 8.03 | 18.62B |
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
UNICYCIVE THERAPEUTICS INC
4300 El Camino Real, Suite 210
Los Altos CALIFORNIA US
CEO: Shalabh Gupta
Employees: 14
Phone: 16503840642
The current stock price of UNCY is 6.34 USD. The price decreased by -5.02% in the last trading session.
The exchange symbol of UNICYCIVE THERAPEUTICS INC is UNCY and it is listed on the Nasdaq exchange.
UNCY stock is listed on the Nasdaq exchange.
UNICYCIVE THERAPEUTICS INC (UNCY) has a market capitalization of 764.79M USD. This makes UNCY a Small Cap stock.
UNICYCIVE THERAPEUTICS INC (UNCY) currently has 14 employees.
UNICYCIVE THERAPEUTICS INC (UNCY) has a support level at 6.33. Check the full technical report for a detailed analysis of UNCY support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
UNCY does not pay a dividend.
UNICYCIVE THERAPEUTICS INC (UNCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
The outstanding short interest for UNICYCIVE THERAPEUTICS INC (UNCY) is 0.31% of its float. Check the ownership tab for more information on the UNCY short interest.
ChartMill assigns a technical rating of 5 / 10 to UNCY. When comparing the yearly performance of all stocks, UNCY is a bad performer in the overall market: 67.59% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to UNCY. UNCY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 59.2% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -119.44% | ||
ROE | -509% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to UNCY. The Buy consensus is the average rating of analysts ratings from 13 analysts.